Drug Category:- Oestrogen
Content:- Gel: Estradiol 0.06%: 80 gm canister with metered pump: 64 doses
Indications:- HRT for oestrogen deficiency symptoms in post menopausal women Second line prevention of post menopausal osteoporosis in women at high risk of future fractures where other therapies are ineffective or inappropriate
Contraindications: Cancer of breast, genital tract or other oestrogen-dependent carcinoma, undiag-nosed vaginal bleeding or endometriosis. Active thrombophlebitis, DVT or thromboembolic disorders, history of venous thromboembolism. Severe cardiac, hepatic or renal disease. Dubin-Johnson or Rotor Syndromes.
Precautions: History or increased risk of thromboem-bolic disorders, BMI >30 kg/m2, prolonged immobili-sation, trauma, surgery. Mild chronic liver disease; monitor liver function every 8 to 12 weeks. Closely monitor patients with cholelithiasis, otosclerosis, mi-graine, multiple sclerosis, epilepsy, diabetes, hyper-tension, asthma, hypercalcaemia, SLE, renal impair-ment, porphyria, uterine fibroids, tetany, breast nodules, fibrocystic disease. There is a small in-creased risk of breast cancer being diagnosed in women on HRT. Take a personal and family medical history and if clinically indicated routinely, perform breast and pelvic examination. Encourage women to self-examine breasts and report changes. If break-through bleeding is persistent, perform endometrial assessment, which may include biopsy. REASONS FOR IMMEDIATE DISCONTINUATION OF TREAT-MENT: Occurrence of migraine-type headaches for the first time, frequent severe headaches, acute visual disturbances, signs of thrombophlebitis or thrombo-embolism, or any other possible prodromal symp-toms of vascular occlusion. Rise in BP, jaundice, hepatitis, itching of the whole body, increase in sei-zures. Pregnancy. Discontinue 6 weeks before major elective surgery and during immobilisation entailing risk of thrombosis.